NCT07209371View on ClinicalTrials.gov

Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 1, 2026

Primary Completion Date

May 1, 2028

Study Completion Date

May 1, 2028

Conditions
IgA Monoclonal Gammopathy of Undetermined Significance
Interventions
DRUG

Rifaximin

Given PO

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

Rising Tide Foundation

OTHER

lead

Fred Hutchinson Cancer Center

OTHER